title: Doxorubicin loading fucoidan acetate nanoparticles for immune and chemotherapy in cancer treatment.
abstract: In order to develop immuno- and chemotherapy agents, self-organized acetylated fucoidan (AcFu) nanoparticles were designed. Doxorubicin (DOX), used as a model drug, was loaded into the AcFu nanoparticles by dialysis. The DOX loading efficacy and content were 71.1% and 3.6%, respectively. Approximately 140 nm of spherical nanoparticles were obtained. DOX-loaded AcFu nanoparticles (DOX-AcFu) exhibited first-order drug release behavior for 5 days. Interestingly, AcFu treated Raw264.7 macrophages overexpressed various anti-tumor cytokines, such as tumor necrosis factor-alpha (TNF-α) and granulocyte-macrophage colony-stimulating factor (GM-CSF). The ability of DOX-AcFu to suppress drug efflux was revealed by confocal microscope images and FACS analysis in multidrug resistance (MDR) cells. IC50 (50% inhibitory concentration) value of DOX-AcFu was lower than that of free DOX in the MDR model cells. Based on these results, we strongly suggest that AcFu nanoparticles have a promising potential for development as a one-step therapy containing agents for both immuno- and chemotherapy.
authors.affiliation: Biotechnology, Department of Life Science, Korea University, Anam-ro 145, Sungbuk-gu, Seoul 136-701, Republic of Korea.
authors.forename: Kun Woo
authors.initials: KW
authors.lastname: Lee
authors.forename: Dooyong
authors.initials: D
authors.lastname: Jeong
authors.forename: Kun
authors.initials: K
authors.lastname: Na
mesh_terms: D000107:Acetylation; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000633:toxicity*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000633:toxicity*; D004337:Drug Carriers / Q000737:chemistry*; D019008:Drug Resistance, Neoplasm; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism; D045325:HCT116 Cells; D006801:Humans; D008264:Macrophages / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D053758:Nanoparticles / Q000737:chemistry*; D009369:Neoplasms / Q000188:drug therapy; D011134:Polysaccharides / Q000138:chemical synthesis / Q000737:chemistry*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D011134:Polysaccharides; D014409:Tumor Necrosis Factor-alpha; D004317:Doxorubicin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; C007789:fucoidan